Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant
- 31 December 2006
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 102 (1-5) , 128-138
- https://doi.org/10.1016/j.jsbmb.2006.09.003
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Adjuvant treatment for early breast cancerAnnals of Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Reversal of tamoxifen resistant breast cancer by low dose estrogen therapyThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Exemestane Following Tamoxifen in Postmenopausal Women With Primary Breast CancerJournal of Clinical Oncology, 2004
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast CancerClinical Pharmacokinetics, 2004
- Overview of the main outcomes in breast-cancer prevention trialsThe Lancet, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifenJournal of Steroid Biochemistry, 1988